Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Novartis beats Street EPS

Novartis (NVS; SWX:NOVN) reported second quarter EPS of $0.49, which was $0.06 better than

Read the full 145 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE